BackSea Mild Biotechnology , Ltd. Overview
Sea Mild Biotechnology Co., Ltd.

Sea Mild Biotechnology , Ltd. Debt to Equity

Sea Mild Biotechnology , Ltd. (7516.TWO) has a debt-to-equity ratio of 1.07, above the sector sector average of 0.98.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

1.07

Debt to Equity

1.07

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Sea Mild Biotechnology , Ltd. (7516.TWO) FAQ

The latest debt-to-equity ratio for 7516.TWO is 1.07. That is above the sector sector average of 0.98. Investors often review this figure alongside Sea Mild Biotechnology , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, 7516.TWO currently prints 1.07 for debt-to-equity ratio, while the sector average sits near 0.98. That is roughly 9.4% above the sector mean. Large gaps often invite a closer look at Sea Mild Biotechnology , Ltd.'s growth, margins, and balance sheet.

A debt-to-equity ratio of 1.07 for Sea Mild Biotechnology , Ltd. is not 'good' or 'bad' on its own. Compare it with the peer average (0.98) and with 7516.TWO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting 7516.TWO's debt-to-equity ratio (1.07), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.